3-取代2-吲哚酮类化合物的合成与抗肿瘤活性研究

目的寻找新的具有血管内皮细胞生长因子受体酪氨酸激酶抑制活性的3-取代2-吲哚酮类化合物。方法以2-吲哚酮为原料，利用缩合反应合成目标化合物，并进行体外初步药效学评价。结果设计并合成了5种化合物，其中4种为首次发现，体外初步药效学研究表明，所合成的化合物均具有抑制S-180肿瘤细胞生长的活性，其中化合物Ⅱ活性最强。结论3-取代2-吲哚酮类化合物具有抑制S-180肿瘤细胞生长的活性，化合物中吲哚环平面与相应的芳环平面之间处于垂直状态时活性较强。     

4-氨基嘧啶取代的双芳基脲类化合物的合成及抗肿瘤细胞增殖活性

目的设计并合成含有不同取代苯环结构的双芳基脲类化合物,初步评价其体外抗肿瘤细胞增殖活性。方法以ABT-869为先导化合物,利用生物电子等排原理,将其3-氨基-1H-吲唑结构改造为氨基嘧啶环设计新目标化合物;以对硝基苯乙腈为起始原料,经与N,N-二甲基甲酰胺二甲缩醛(DMF-DMA)缩合、环合、还原、酰化、成脲共5步反应合成目标化合物;以索拉非尼(sorafenib)为阳性对照药,采用MTT法,测试目标化合物对乳腺癌细胞株MDA-MB-231的抗增殖活性。结果与结论合成了18个未见报道的双芳基脲类化合物,其结构经1H-NMR和MS谱确证;6个化合物显示较好的体外活性,其中,化合物5r活性突出,为对照药索拉非尼的1.8倍;并且初步探讨了目标化合物的构效关系。     

1H-1,2,3-三氮唑乙酸酯衍生物的合成与体外抗乙肝病毒活性研究

目的 设计合成1H-1,2,3-三氮唑环衍生物，并测定其体外抗乙肝病毒活性。方法 以取代吲哚为原料，经取代、环加成反应得到14个目标化合物，通过¹H-NMR、¹³C-NMR和MS方法对化合物的结构进行表征，以HepG2.2.15为细胞模型进行抗乙肝病毒体外活性实验，测试化合物在体外对乙肝病毒e抗原(HBeAg)和乙肝病毒表面抗原(HBsAg)分泌的影响。结果与结论其中4个目标化合物能较好地抑制HBeAg和HBsAg的分泌，化合物2-(4-((5-氯-1H-吲哚-1-基)甲基)-1H-1,2,3-三唑-1-基)乙酸乙酯(IC₅₀=75.41μmol·L^-1,SI=9.23)能较好抑制HBV DNA。吲哚5号位含有吸电子基团卤素原子的化合物对抑制乙肝病毒的分泌效果较好。     

β-榄香烯吲哚衍生物的合成及其体外抗K562细胞增殖活性

目的设计合成β-榄香烯吲哚衍生物并进行体外抗癌活性筛选。方法通过合成β-榄香烯氯代物,在其结构中引入3-吲哚乙胺结构片段进而合成β-榄香烯吲哚衍生物。采用MTT法测定目标化合物对K562白血病细胞的增殖抑制作用。结果合成了15个未见文献报道的β-榄香烯吲哚衍生物。目标化合物的结构经1H-NMR、MS谱确证。活性实验结果显示14个目标化合物的活性高于β-榄香烯。结论在β-榄香烯结构中引入3-吲哚乙胺结构片段有利于提高此类化合物的抗癌活性。     

新型环丙烷类B-Raf激酶抑制剂的设计合成及抗肿瘤活性研究

目的设计合成一系列环丙烷类B-Raf激酶抑制剂并测定其对人肝癌Hep G2细胞增殖的影响。方法以索拉非尼(sorafenib)为先导化合物,通过结构优化设计新型环丙烷类B-Raf激酶抑制剂,并以对羟基苯甲醛为起始原料经过苄基保护、缩合、酯化、环丙化、水解、酰胺化、脱苄、亲核取代等反应合成目标化合物。以索拉非尼为阳性对照物,采用MTT法测定目标化合物对人肝癌HepG2细胞增殖的影响。结果与结论合成了16个未见文献报道的新化合物,其结构经核磁共振氢谱鉴定。初步的体外活性评价结果表明,其中9个化合物表现出良好的肿瘤细胞抑制活性,优于阳性对照药索拉非尼,具有进一步研究的价值。     

新型微管稳定剂吲哚美辛衍生物的合成与抗肿瘤活性研究

目的设计合成一系列吲哚美辛衍生物并测定其体外抗肿瘤和微管蛋白抑制活性。方法以5-甲氧基-2-甲基-3-吲哚乙酸为起始原料经两步酰化反应合成12个化合物,MTT法检测目标化合物对HT29、A549、Hep-2、MCF-7肿瘤细胞的抑制活性,同时采用浊度法评价其体外微管蛋白的抑制作用。结果 12种目标化合物均呈现了优于吲哚美辛的体外抗肿瘤作用和微管蛋白抑制活性,其中3位羧基侧链苯乙基取代的化合物12作用于人结肠癌细胞HT29的IC_(50)(2.2μmol)为吲哚美辛的400倍,并且可以干扰微管聚合,其作用于微管蛋白的IC_(50)为5.6μmol。结论改变吲哚美辛1位酰胺和3位羧酸侧链所得的系列衍生物是一类新型的以微管为靶点的抗肿瘤候选药物。     

5-羟基-1H-吲哚-3-羧酸乙酯类化合物的合成及其抗流感病毒活性

目的设计合成5-羟基-1H-吲哚-3-羧酸乙酯类化合物,评价其抗流感病毒和抗呼吸道合胞病毒活性.方法经IR、1H-NMR和MS确证目标物结构,并经体外抗病毒试验进行活性筛选.结果与结论合成了9个5-羟基-1H-吲哚-3-羧酸乙酯类化合物,初步活性试验表明,具有一定的抑制流感病毒和呼吸道合胞病毒作用,其中,化合物Ⅷ1、Ⅷ2、Ⅷ5的抗病毒活性与利巴韦林和阿比朵尔相当.     

新型吲哚类胆固醇酯转运蛋白抑制剂的设计、合成及生物活性研究

目的设计并合成一系列以吲哚为母核的新型小分子胆固醇酯转运蛋白(CETP)抑制剂,并初步评价其体外抑制活性。方法以实验室前期获得的化合物Ⅰ为先导化合物,主要对其吲哚母环的2,3,5位进行修饰改造。以吲哚-2-羧酸乙酯衍生物为原料,通过还原、氧化、还原胺化、取代、Suzuki偶联、亲核取代反应制备得到8个目标化合物;以吲哚或吲哚-2-羧酸乙酯为原料,经Vilsmeier反应在3位引入醛基,再经过还原胺化、取代、Suzuki偶联、亲核取代得到7个目标化合物;进一步通过对2位酯基水解或经还原、烷基化得到另外2个目标化合物。采用BODIPY-CE荧光分析法,以anacetrapib为阳性对照药,测试目标化合物体外对CETP的抑制活性。结果与结论合成了17个未见报道的新化合物,结构经~1H-NM R、M S、~(13)C-NM R谱确证;活性测试表明该类化合物具有中等强度的CETP抑制活性,其中化合物10h的活性较先导化合物有接近10倍的提高,为今后该类化合物的结构优化提供了重要指导。     

沙利度胺衍生物的设计合成及其抗肿瘤活性研究

目的设计合成1，3-二氢-1，3-二氧代．2H-异吲哚-N-取代沙利度胺衍生物。并对其进行体外抗肿瘤活性测试。方法以2．氨基-β-D-吡喃葡萄糖盐酸盐为原料，经过6步反应得到化合物N-（3’，4’，6＇-三乙酰-1’-溴代吡喃葡萄糖）-1,3-二氢-1，3-二氧代-2H-异吲哚，该化合物经过溴代、取代反应得到目标化合物。通过对4T1细胞存活率的测试测定20个目标化合物体外抗肿瘤活性。结果设计合成的20个目标化合物均未见文献报道。所有化合物均经过1H-NMR谱确证，部分化合物经IR、MS谱确证。结论所有目标化合物对4T1细胞均具有-定的抑制生长作用。表明所合成的沙利度胺衍生物均有-定的抗肿瘤活性。     

一锅法合成新型吲哚-色胺酮类化合物

目的合成新型结构的吲哚-色胺酮[6-(1H-吲哚-2-基)吲哚并[2,1-b]喹唑啉-12(5H)-酮]类化合物,并初步考察其代表性化合物3a的抗肿瘤活性。方法以2-吲哚酮为起始原料,经盐酸酸化后在过量三氯氧磷的条件下与相应的取代2-氨基苯甲酸经一锅法合成新的吲哚-色胺酮类化合物。采用MTT法考察化合物3a对不同肿瘤细胞的抑制作用。结果与结论合成了3个未见报道的新化合物,目标化合物的结构经质谱、核磁共振谱确证。活性测试结果表明,化合物3a对A549肿瘤细胞株显示出一定的抑制作用。目标化合物是在色胺酮结构中引入吲哚单元后形成的新骨架结构的化合物,将为进一步研究基于吲哚-色胺酮结构的先导化合物提供一个新的方向。     

5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design,synthesis, molecular docking,and anticancer evaluations

A novel series of 5-(4-methoxybenzylidene)thiazolidine-2,4-dione derivatives, 5a–g and 7a–f , was designed, synthesized, and evaluated for their anticancer activity against HepG2, HCT116, and MCF-7 cells. HepG2 and HCT116 were the most sensitive cell lines to the influence of the new derivatives. In particular, compounds 7f , 7e , 7d , and 7c were found to be the most potent derivatives of all the tested compounds against the HepG2, HCT116, and MCF-7 cancer cell lines. Compound 7f (IC₅₀ = 6.19 ± 0.5, 5.47 ± 0.3, and 7.26 ± 0.3 µM, respectively) exhibited a higher activity than sorafenib (IC₅₀ = 9.18 ± 0.6, 8.37 ± 0.7, and 5.10 ± 0.4 µM, respectively) against HepG2 and MCF-7, cells but a lower activity against HCT116 cancer cells, respectively. Also, this compound displayed a higher activity than doxorubicin (IC₅₀ = 7.94 ± 0.6, 8.07 ± 0.8, and 6.75 ± 0.4 µM, respectively) against HepG2 and MCF-7 cells, but nearly the same activity against HCT116 cells, respectively. All derivatives, 5a–g and 7a–f , were evaluated for their inhibitory activities against vascular endothelial growth factor receptor-2 (VEGFR-2). Among them, compound 7f was found to be the most potent derivative that inhibited VEGFR-2 at an IC₅₀ value of 0.12 ± 0.02 µM, which is nearly the same as that of sorafenib (IC₅₀ = 0.10 ± 0.02 µM). Compounds 7e , 7d , 7c , and 7b exhibited the highest activity, with IC₅₀ values of 0.13 ± 0.02, 0.14 ± 0.02, 0.14 ± 0.02, and 0.18 ± 0.03 µM, respectively, which are more than the half of that of sorafenib. Furthermore, molecular docking was performed to investigate their binding mode and affinities toward the VEGFR-2 receptor. The data obtained from the docking studies highly correlated with those obtained from the biological screening.     

Design,synthesis, molecular docking,and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors

A novel series of 1-benzylquinazoline-2,4(1H,3H)-dione derivatives, 6a , b to 11a – e , was designed, synthesized, and evaluated for their anticancer activity against HepG2, HCT-116, and MCF-7 cells. Compounds 11b , 11e , and 11c were found to be the most potent derivatives of all tested compounds against the HepG2, HCT-116, and MCF-7 cancer cell lines, with GI₅₀ = 9.16 ± 0.8, 5.69 ± 0.4, 5.27 ± 0.2 µM, 9.32 ± 0.9, 6.37 ± 0.7, 5.67 ± 0.5 µM, and 9.39 ± 0.5, 6.87 ± 0.7, 5.80 ± 0.4 µM, respectively. These compounds exhibited nearly the same activity as sorafenib against HepG2 and HCT-116 cells and a higher activity against MCF-7 cells (GI₅₀ = 9.18 ± 0.6, 5.47 ± 0.3, and 7.26 ± 0.3 µM, respectively). Also, these compounds displayed a lower activity than doxorubicin against HepG2 cells and a higher activity against HCT-116 and MCF-7 cells (GI₅₀ = 7.94 ± 0.6, 8.07 ± 0.8, and 6.75 ± 0.4 µM, respectively). The most active antiproliferative derivatives, 6a , b , 8 , 9 , and 11a – e , were selected to evaluate their enzymatic inhibitory activity against VEGFR-2. Compounds 11b , 11e , and 11c potently inhibited VEGFR-2 at IC₅₀ values of 0.12 ± 0.02, 0.12 ± 0.02, and 0.13 ± 0.02 µM, respectively, which are nearly equipotent as sorafenib IC₅₀ value (0.10 ± 0.02 µM). Furthermore, molecular docking studies were performed for all synthesized compounds to assess their binding pattern and affinity toward the VEGFR-2 active site.     

4,6-双苯基-2-氨基-3-氰基吡啶类化合物的合成及其 抗肿瘤活性研究

目的 设计合成一系列4,6-双苯基-2-氨基-3-氰基吡啶类化合物,并对其体外抗肿瘤活性进行初步评价。方法 以取代苯甲醛、取代苯乙酮、丙二腈和醋酸铵为原料,经一步反应制得目标化合物。采用MTT法,以 MX-58151 为阳性对照药,以 A549、HT-29 和 SMMC-7721为测试细胞株对目标化合物进行体外抗肿瘤活性评价。 结果与结论 合成了13 个未见报道的4,6-双苯基-2-氨基-3-氰基吡啶类化合物, 其结构经¹H-NMR、MS 和 IR 谱确证。体外活性测试结果显示,多数化合物能够在较低的浓度下抑制肿瘤细胞增殖。其中,2-氨基-6-（4-氟苯基）-4-（2,3,4-三甲氧基苯基）-3-氰基吡啶 具有显著的抗肿瘤细胞增殖活性,IC₅₀值达纳摩尔级水平,明显优于阳性对照药MX-58151。     

Synthesis and evaluation in vitro of 1-[2-(10-dihydroartemisininoxy) ethyl]-3-phenylurea derivatives as potential agents against cancer

In order to develop potent and selective anticancer agents, a series of novel artemisinin derivatives bearing urea moiety 1a–n were facilely synthesized herein and screened for their activities in vitro against ten human tumor cell lines (HeLa, MCF-7, U937, K562, HL60, HCT116, HepG2, A549, A375-S2, and HT1080). The pharmacological results indicated that some compounds showed excellent activity against cancer cell lines and good selectivity, especially the compound 1c which proved to be the most active against the cancer cells as well as distinctive patterns of selectivity.     

Synthesis of 1H-pyrazole-1-carboxamide derivatives and their antiproliferative activity against melanoma cell line

Synthesis of a new series of 1H-pyrazole-1-carboxamide derivatives is described. Their antiproliferative activity against A375 human melanoma cell line was tested and the effect of substituents on the diarylpyrazole scaffold was investigated. The pharmacological results indicated that most of the newly synthesized compounds showed moderate activity against A375, compared with sorafenib. Among all of these derivatives, compound IIe which has N-methylpiperazinyl and phenolic moieties showed the most potent antiproliferative activity against A375 human melanoma cell line.     

TLR4基因多态性对索拉菲尼治疗肝癌的影响及相关分子机制

目的：研究TLR4基因多态性对索拉菲尼治疗肝癌的影响并探讨其相关分子机制。方法：CCK-8法检测索拉菲尼对各细胞的抑制率，并计算索拉菲尼在不同组细胞的IC₅₀；Annexin V-FITC/PI双染法检测各组细胞使用索拉菲尼后的凋亡情况，再与未使用索拉菲尼时各组细胞的凋亡率进行比较；Western-blot检测TLR4信号通路蛋白JNK、P-JNK、ERK及P-ERK的表达水平。结果：与野生型细胞株相比，突变型细胞株能够显著性促进索拉菲尼对肝癌细胞HepG2的抑制率，并且索拉菲尼在突变型细胞组的IC₅₀值显著性低于野生型细胞组，流式凋亡检测表明，索拉菲尼对突变型细胞株的促凋亡作用较野生型细胞株更强。Western blot结果表明野生型细胞株中P-JNK和P-ERK的表达水平较突变型细胞高，差异具有显著性（P<0.05）。结论：TLR4基因多态性可以通过调控JNK及ERK信号通路来促进肝癌细胞HepG2对索拉菲尼的敏感性。     

Design and synthesis of 2-iminothiazolidin-4-one moiety-containing compounds as potent antiproliferative agents

A new series of 2,5‐diaryliminothiazolidin‐4‐ones were designed and synthesized as potent antiproliferative agents. The antiproliferative activities of the 25 target compounds were evaluated against three cancer cell lines (A549, H460 and HT29) by MTT assay. Pharmacological data indicated that most of the compounds possessed moderate activity, some showed remarkable activity against one or more cell lines. As the most promising compound, 8s (with IC₅₀ values of 1.1, 0.01 and 1.3 µM against the A549, H460 and HT29 cell lines) was 1.1‐ to 270‐fold more potent than the reference drug sorafenib. Furthermore, preliminary structure–activity relationships (SARs) were summarized to provide guidance for further design and discovery of 2‐iminothiazolidin‐4‐one‐based antiproliferative agents.     

薯蓣皂苷元衍生物的抗肿瘤活性研究

目的研究薯蓣皂苷元衍生物在体外的抗肿瘤活性。方法采用MTT法对人恶性黑色素瘤细胞A375、人肺腺癌细胞A549、人肝癌细胞HepG-2及人慢性髓原白血病细胞株K562进行体外抗肿瘤活性试验。结果薯蓣皂苷元衍生物对4个肿瘤细胞株A375、A549、K562、HepG-2具有不同程度的抗肿瘤活性。结论绝大部分薯蓣皂苷元衍生物对4个肿瘤细胞株有较好的抗肿瘤活性,IC50值都低于30μmol.L-1。化合物22对细胞株A375的IC50=4.48μmol.L-1,化合物9、10对细胞株K562的IC50分别为2.51、2.38μmol.L-1;显示其抗肿瘤活性与对照化合物1-(3β-薯蓣皂苷元)-3-苄基咪唑溴盐相当。     

Design and synthesis of 1-substituted-β-carboline derivatives as potential anticancer agents

In the present study, we designed and synthesized a series of 1-substituted-β-carboline derivatives through modification of position-1, 2 and 9 of β-carboline nucleus in order to discover novel leading compounds with better antitumor activities and less toxicity. Their structures were confirmed by ¹H NMR, ¹³C NMR, MS, IR and elemental analyses. All the target compounds were tested for cytotoxic activity against six cancer cell lines, including Bel-7402, HepG2, A549, A375, 786-0 and HT-29 by methyl thiazolyl tetrazolium (MTT) method. Studies of structure-activity relationships indicated that the effects of substituents in position-1 on cytotoxic activities were in an order as follows: 2-thienyl >2-chlorophenyl >4-chlorophenyl >benzyl group.     

Design, synthesis and evaluation of novel rhodanine-containing sorafenib analogs as potential antitumor agents

A series of rhodanine-containing sorafenib analogs was designed, synthesized and evaluated for their in-vitro antitumor activity against three cancer cell lines (A549, H460 and HT29). Pharmacological data indicated that some of the target compounds possessed marked antiproliferative activity superior to the reference drug sorafenib, especially the most promising compound 7r (with the IC(50) value of 0.8, 1.3 and 2.8 μM against A549, H460 and HT29 cell lines, respectively). The activity was found to strongly depend on the substitution pattern of the rhodanine motif at C-5″ position. Results suggested that this series of compounds could serve as the bases for the development of novel antitumor agents.